<unk>  (Emend for Injection (US), Ivemend (EU)) is an antiemetic medication, administered intravenously. It is a prodrug of aprepitant.<unk>  was developed by Merck & Co. and was approved by the U.S. Food and Drug Administration (FDA) on January 25, 2008, and by the European Medicines Agency (EMA) on January 11 of the same year.
Fosaprepitant
Furegrelate
Bocasan
Tezacaftor
Lemborexant
Eteplirsen
Vigabatrin
Pleconaril